Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Prediction of Nephropathy in Type 2 Diabetes: An Analysis of the ACCORD Trial Applying Machine Learning Techniques.

Rodriguez-Romero V, Bergstrom RF, Decker BS, Lahu G, Vakilynejad M, Bies RR.

Clin Transl Sci. 2019 Sep;12(5):519-528. doi: 10.1111/cts.12647. Epub 2019 May 31.

2.

Pharmacokinetics of olanzapine long-acting injection: the clinical perspective.

Heres S, Kraemer S, Bergstrom RF, Detke HC.

Int Clin Psychopharmacol. 2014 Nov;29(6):299-312. doi: 10.1097/YIC.0000000000000040.

3.

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.

McDonnell DP, Detke HC, Bergstrom RF, Kothare P, Johnson J, Stickelmeyer M, Sanchez-Felix MV, Sorsaburu S, Mitchell MI.

BMC Psychiatry. 2010 Jun 10;10:45. doi: 10.1186/1471-244X-10-45.

4.

Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model.

Lobo ED, Robertson-Plouch C, Quinlan T, Hong Q, Bergstrom RF.

Paediatr Drugs. 2010 Jun;12(3):201-11. doi: 10.2165/11532580-000000000-00000.

PMID:
20297865
5.

Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.

Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D.

Am J Psychiatry. 2010 Feb;167(2):181-9. doi: 10.1176/appi.ajp.2009.07081221. Epub 2009 Dec 15.

PMID:
20008947
6.

Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration.

Citrome L, Stauffer VL, Chen L, Kinon BJ, Kurtz DL, Jacobson JG, Bergstrom RF.

J Clin Psychopharmacol. 2009 Jun;29(3):278-83. doi: 10.1097/JCP.0b013e3181a289cb.

PMID:
19440083
7.

In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine.

Lobo ED, Bergstrom RF, Reddy S, Quinlan T, Chappell J, Hong Q, Ring B, Knadler MP.

Clin Pharmacokinet. 2008;47(3):191-202.

PMID:
18307373
8.

Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women.

Lobo ED, Loghin C, Knadler MP, Quinlan T, Zhang L, Chappell J, Lucas R, Bergstrom RF.

Clin Pharmacokinet. 2008;47(2):103-9.

PMID:
18193916
9.

Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects.

Sathirakul K, Chan C, Teng L, Bergstrom RF, Yeo KP, Wise SD.

Br J Clin Pharmacol. 2003 Aug;56(2):184-7.

10.

Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia.

Grothe DR, Calis KA, Jacobsen L, Kumra S, DeVane CL, Rapoport JL, Bergstrom RF, Kurtz DL.

J Clin Psychopharmacol. 2000 Apr;20(2):220-5.

PMID:
10770461
11.

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM.

Clin Pharmacokinet. 1999 Sep;37(3):177-93. Review.

PMID:
10511917
12.

A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism.

Lucas RA, Gilfillan DJ, Bergstrom RF.

Eur J Clin Pharmacol. 1998 Oct;54(8):639-43.

PMID:
9860152
13.

Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men.

Macias WL, Bergstrom RF, Cerimele BJ, Kassahun K, Tatum DE, Callaghan JT.

Pharmacotherapy. 1998 Nov-Dec;18(6):1237-48.

PMID:
9855322
14.

Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine.

Bergstrom RF, Goldberg MJ, Cerimele BJ, Hatcher BL.

Clin Pharmacol Ther. 1997 Dec;62(6):643-51.

PMID:
9433393
15.

The effect of sertraline on the pharmacokinetics of desipramine and imipramine.

Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ.

Clin Pharmacol Ther. 1997 Aug;62(2):145-56.

PMID:
9284850
16.

Fluoxetine in depressed patients on dialysis.

Blumenfield M, Levy NB, Spinowitz B, Charytan C, Beasley CM Jr, Dubey AK, Solomon RJ, Todd R, Goodman A, Bergstrom RF.

Int J Psychiatry Med. 1997;27(1):71-80.

PMID:
9565715
17.

The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine.

Bergstrom RF, Beasley CM Jr, Levy NB, Blumenfield M, Lemberger L.

Int Clin Psychopharmacol. 1993 Winter;8(4):261-6. Review.

PMID:
8277145
18.

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction.

Bergstrom RF, Peyton AL, Lemberger L.

Clin Pharmacol Ther. 1992 Mar;51(3):239-48.

PMID:
1544284
19.

Secretion of nizatidine into human breast milk after single and multiple doses.

Obermeyer BD, Bergstrom RF, Callaghan JT, Knadler MP, Golichowski A, Rubin A.

Clin Pharmacol Ther. 1990 Jun;47(6):724-30.

PMID:
1972674
20.

Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion.

Schneck DW, Callaghan JT, Bergstrom RF, Obermeyer BD, Offen WW.

Clin Pharmacol Ther. 1990 Apr;47(4):499-503.

PMID:
2109665
21.

Clinical pharmacokinetics of intravenously injected tritiated vinzolidine.

Kreis W, Budman DR, Freeman J, Bergstrom RF, Nelson RL.

Cancer Chemother Pharmacol. 1990;26(6):419-22.

PMID:
2225313
22.

Efficacy of prophylactic antibiotics in vascular surgery: an arterial wall microbiologic and pharmacokinetic perspective.

Lalka SG, Malone JM, Fisher DF Jr, Bernhard VM, Sullivan D, Stoeckelmann D, Bergstrom RF.

J Vasc Surg. 1989 Nov;10(5):501-9; discussion 509-10.

PMID:
2810536
23.

Fluoxetine disposition and elimination in cirrhosis.

Schenker S, Bergstrom RF, Wolen RL, Lemberger L.

Clin Pharmacol Ther. 1988 Sep;44(3):353-9.

PMID:
3262026
24.

Clinical pharmacology and pharmacokinetics of fluoxetine: a review.

Bergstrom RF, Lemberger L, Farid NA, Wolen RL.

Br J Psychiatry Suppl. 1988 Sep;(3):47-50. Review. No abstract available.

PMID:
3074865
25.

Nizatidine disposition in subjects with normal and impaired renal function.

Aronoff GR, Bergstrom RF, Bopp RJ, Sloan RS, Callaghan JT.

Clin Pharmacol Ther. 1988 Jun;43(6):688-95.

PMID:
2897890
26.

The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.

Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF.

Clin Pharmacol Ther. 1988 Apr;43(4):412-9.

PMID:
3128416
27.

Absorption studies of the H2-blocker nizatidine.

Knadler MP, Bergstrom RF, Callaghan JT, Obermeyer BD, Rubin A.

Clin Pharmacol Ther. 1987 Nov;42(5):514-20. Erratum in: Clin Pharmacol Ther 1991 Mar;49(3):255.

PMID:
2890459
28.

Nizatidine, and H2-receptor antagonist: disposition and safety in the elderly.

Callaghan JT, Rubin A, Knadler MP, Bergstrom RF.

J Clin Pharmacol. 1987 Aug;27(8):618-24.

PMID:
2888796
29.

Fluoxetine, pharmacology and physiologic disposition.

Lemberger L, Farid NA, Bergstrom RF, Wolen RL.

Int J Obes. 1987;11 Suppl 3:157-61. No abstract available.

PMID:
3501991
30.

A pharmacokinetic profile of nizatidine in man.

Callaghan JT, Bergstrom RF, Rubin A, Chernish S, Crabtree R, Knadler MP, Obermeyer B, Offen WW, Schneck DW, Aronoff G, et al.

Scand J Gastroenterol Suppl. 1987;136:9-17. Review. Erratum in: Scand J Gastroenterol Suppl 1991 Aug;26(8):preceding 801.

PMID:
2892261
31.

Nizatidine, an H2-blocker. Its metabolism and disposition in man.

Knadler MP, Bergstrom RF, Callaghan JT, Rubin A.

Drug Metab Dispos. 1986 Mar-Apr;14(2):175-82.

PMID:
2870891
32.

Effect of fluoxetine on psychomotor performance, physiologic response, and kinetics of ethanol.

Lemberger L, Rowe H, Bergstrom RF, Farid KZ, Enas GG.

Clin Pharmacol Ther. 1985 Jun;37(6):658-64.

PMID:
3874037
33.

Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects.

Farid NA, Bergstrom RF, Ziege EA, Parli CJ, Lemberger L.

J Clin Pharmacol. 1985 May-Jun;25(4):296-301.

PMID:
4008676
34.

Fluoxetine: clinical pharmacology and physiologic disposition.

Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR.

J Clin Psychiatry. 1985 Mar;46(3 Pt 2):14-9.

PMID:
3871765
35.

Intravenous nizatidine kinetics and acid suppression.

Callaghan JT, Bergstrom RF, Obermeyer BD, King EP, Offen WW.

Clin Pharmacol Ther. 1985 Feb;37(2):162-5.

PMID:
2857117
36.

Fluoxetine kinetics and protein binding in normal and impaired renal function.

Aronoff GR, Bergstrom RF, Pottratz ST, Sloan RS, Wolen RL, Lemberger L.

Clin Pharmacol Ther. 1984 Jul;36(1):138-44.

PMID:
6610522
37.

Clinical pharmacology of benoxaprofen.

Ridolfo AS, Carmichael RH, DeSante KA, Bergstrom RF, Rockhold FW, Nash JF, Fineberg SE.

Eur J Rheumatol Inflamm. 1982;5(2):98-112.

PMID:
7084287
38.

The pharmacokinetics of penicillamine in a female mongrel dog.

Bergstrom RF, Kay RD, Wagner JG.

J Pharmacokinet Biopharm. 1981 Oct;9(5):603-21.

39.

Penicillamine kinetics in normal subjects.

Bergstrom RF, Kay DR, Harkcom TM, Wagner JG.

Clin Pharmacol Ther. 1981 Sep;30(3):404-13.

40.

Plasma protein-binding parameters of prednisolone in immune disease patients receiving long-term prednisone therapy.

Wagner JG, Wexler D, Ağabeyoğlu IT, Bergstrom RF, Sakmar E, Kay DR.

J Lab Clin Med. 1981 Apr;97(4):487-501.

PMID:
7205057
41.
42.
43.

Plasma protein binding of prednisolone in normal volunteers and arthritic patients.

Ağabeyoğlu IT, Bergstrom RF, Gillespie WR, Wagner JG, Kay DR.

Eur J Clin Pharmacol. 1979;16(6):399-404. No abstract available.

44.

Stability of parenteral solutions of tobramycin sulfate.

Bergstrom RF, Fites AL, Lamb JW.

Am J Hosp Pharm. 1975 Sep;32(9):887-8.

PMID:
242216
45.

Letter: Stability of erythromycin gluceptate in sodium chloride injection and dextrose injection.

Bergstrom RF, Fites AL.

Am J Hosp Pharm. 1975 Mar;32(3):241. No abstract available.

PMID:
237418

Supplemental Content

Loading ...
Support Center